Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Purpose of DNA tetrahedron in preparation of medicine capable of treating renal injury

A technology of tetrahedron and kidney damage, which can be applied in the direction of drug combination, pharmaceutical formula, medical preparations containing active ingredients, etc., and can solve problems such as obvious side effects and application limitations

Active Publication Date: 2021-04-02
SICHUAN UNIV
View PDF1 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] There are only a handful of drugs for the treatment of kidney injury that have been found so far, and there are obvious side effects, which lead to many limitations in their application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Purpose of DNA tetrahedron in preparation of medicine capable of treating renal injury
  • Purpose of DNA tetrahedron in preparation of medicine capable of treating renal injury
  • Purpose of DNA tetrahedron in preparation of medicine capable of treating renal injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Synthesis and identification of embodiment 1 tFNAs

[0027] 1. Synthesis method

[0028] Dissolve the four DNA single strands (S1, S2, S3, S4) in TM Buffer (10mM Tris-HCl, 50mM MgCl 2 , pH=8.0), the final concentration of the four DNA single strands was 1000nM, mixed thoroughly, rapidly heated to 95°C for 10 minutes, and then rapidly cooled to 4°C and maintained for more than 20 minutes to obtain tFNAs.

[0029] The sequences of the four single strands (5'→3') are as follows:

[0030]

[0031] 2. Identification

[0032] After synthesis of tFNAs, SDS-PAGE electrophoresis shows that tFNAs is about 200bp, it can be considered that tFNAs have been successfully synthesized ( figure 1 ). Using transmission electron microscopy, the tetrahedral structure of tFNAs characteristics can be seen under the microscope ( figure 2 ).

[0033] The present invention will be further described in the form of experimental examples below.

experiment example 1

[0034] Experimental example 1 Distribution of tFNAs in mice

[0035] 1. Method

[0036] The fluorescent molecule Cy5 was used to label tFNAs, half an hour after intravenous injection (injection volume: 40 microliters) of Balb / c mice, each tissue and organ was collected, and the fluorescence of each tissue and organ was detected by a small animal imaging system.

[0037] 2. Results

[0038] The fluorescence intensity of cy5-tFNAs in the mouse liver, kidney and gallbladder was stronger, among which the fluorescence intensity of tFNAs in the gallbladder was the highest, followed by the kidney ( image 3 ).

[0039] The results of this experimental example show that tFNAs can be enriched in the kidney, which is conducive to its therapeutic effect.

experiment example 2

[0040] Experimental example 2 Animal experiments on the curative effect of tFNAs on kidney injury

[0041] 1. Method

[0042] Glycerol (8 mg / kg) was intramuscularly injected into the hind limbs of balb / c mice to establish a rhabdomyolysis-induced acute kidney injury mouse (AKI mouse) model. At the same time, the healthy mice injected with saline into their hind limbs were regarded as the sham operation group; the mice without any treatment were regarded as the blank group. 2 hours after modeling, inject tFNAs into AKI mice (40 μl, concentration: 1 μmol / L) as the tFNAs group, inject normal saline (40ul) into the tail vein of AKI mice (for the AKI group) and the mice of the sham operation group . After 24 hours, the kidney tissues of the mice were collected, fixed and made into paraffin sections for HE staining.

[0043] 2. Results

[0044] The result is as Figure 4 As shown, compared with normal renal histopathology, renal tubular epithelial cells in the AKI group were sw...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a new purpose of a DNA tetrahedron in preparation of a medicine capable of treating renal injury, and belongs to the field of nucleic acid medicines. The invention proves that the DNA tetrahedron can repair injured renal tubular epithelial cells, and discloses the new purpose of the DNA tetrahedron used for treating the renal injury. Since the DNA tetrahedron has high biocompatibility and few medicines used for treating the renal injury are in the presence at present, the new purpose disclosed by the invention has a good application value.

Description

technical field [0001] The invention belongs to the field of nucleic acid medicines, and in particular relates to the use of DNA tetrahedrons in the preparation of medicines for treating kidney damage. Background technique [0002] The kidney is an important organ for excreting metabolic waste in the body, and its importance is self-evident. External mechanical force and exogenous compounds (such as: gentamicin, contrast agent, cisplatin, lipopolysaccharide, glycerin, etc.) can directly or indirectly damage the renal tubular epithelial tissue, leading to renal injury, which seriously threatens health and even life. [0003] Direct damage to renal tubular epithelial tissue refers to damage to renal tubular epithelial tissue caused by mechanical external force, or direct toxicity of exogenous compounds to renal tubular epithelial tissue. For example: after gentamicin enters the human body, it is hardly metabolized, most of it is filtered by the glomerulus, part of it is reabs...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/711A61P13/12
CPCA61K31/711A61P13/12
Inventor 林云锋张琦蔡潇潇林世宇
Owner SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com